Coupling between phosphoinositide breakdown and early mitogenic events in fibroblasts. Studies with fluoroaluminate, vanadate, and pertussis toxin.
In the preceding paper (Paris, S., and Pouysségur J. (1987) J. Biol. Chem. 262, 1970-1976), AlF4- and vanadate have been shown to induce inositol phosphate formation in resting hamster fibroblasts (CCL39). In this study, we show that these two phosphate analogs are good tools to explore the causal relationship between phosphoinositide breakdown and early mitogenic events. AlF4- can activate, very similarly to the mitogen alpha-thrombin: the amiloride-sensitive Na+/H+ antiport, the bumetanide-sensitive Na+/K+/Cl- co-transport, and the expression of c-myc mRNA. The link between phospholipase C activation and these early events of the mitogenic response is demonstrated by the similarity of all dose-response curves for NaF and AlCl3 and by the common sensitivity of the four events to pertussis toxin. Vanadate likewise stimulates the Na+/H+ antiport through a pertussis toxin-sensitive pathway. On longer incubations, both fluoride and vanadate were found to be toxic and failed to induce DNA synthesis. Therefore, we have used pertussis toxin to investigate the link between phospholipase C activation and commitment to DNA synthesis. We show that pertussis toxin strikingly inhibits thrombin-induced reinitiation of DNA synthesis but does not affect the stimulation by the epidermal or fibroblast growth factors, two mitogens that do not stimulate phosphoinositide breakdown in CCL39 cells. In conclusion, these studies demonstrate that activation of phospholipase C, if not an obligatory step in the action of all growth factors, plays a crucial role in the mitogenic signaling pathway of alpha-thrombin.
D000535:Aluminum / Q000494:pharmacology*; D000077410:Aluminum Chloride; D017607:Aluminum Compounds; D000584:Amiloride / Q000494:pharmacology; D000818:Animals; D002034:Bumetanide / Q000494:pharmacology; D002352:Carrier Proteins / Q000378:metabolism; D002712:Chlorides / Q000494:pharmacology; D006224:Cricetinae; D003412:Cricetulus; D004261:DNA Replication / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004789:Enzyme Activation; D005347:Fibroblasts / Q000166:cytology*; D005459:Fluorides; D005461:Fluorine / Q000494:pharmacology*; D006863:Hydrogen-Ion Concentration; D008938:Mitosis; D037342:Pertussis Toxin; D010716:Phosphatidylinositols / Q000378:metabolism*; D012969:Sodium Fluoride / Q000494:pharmacology; D017923:Sodium-Hydrogen Exchangers; D013917:Thrombin / Q000494:pharmacology; D010738:Type C Phospholipases / Q000378:metabolism; D014638:Vanadates; D014639:Vanadium / Q000494:pharmacology*; D010566:Virulence Factors, Bordetella / Q000494:pharmacology*
D017607:Aluminum Compounds; D002352:Carrier Proteins; D002712:Chlorides; D010716:Phosphatidylinositols; D017923:Sodium-Hydrogen Exchangers; D010566:Virulence Factors, Bordetella; D014639:Vanadium; D002034:Bumetanide; C050992:tetrafluoroaluminate; D005461:Fluorine; D000077410:Aluminum Chloride; D014638:Vanadates; D000584:Amiloride; D012969:Sodium Fluoride; D000535:Aluminum; D037342:Pertussis Toxin; D010738:Type C Phospholipases; D013917:Thrombin; D005459:Fluorides